Loading
A phase 1/2 trial of Afuresertib run by Laekna Limited, completed.
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 is a phase 1/2 interventional study registered as NCT05383482 by Laekna Limited, with 22 participants enrolled, started 2022-07-01, primary completion reached 2024-06-25. Conditions recorded: Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gastric and Gastroesophageal Junction Adenocarcinoma. Interventions recorded: Afuresertib, Nab paclitaxel, Docetaxel, Sintilimab.
Shares Afuresertib, Laekna Therapeutics and the tag pipeline.
Shares Afuresertib, Laekna Therapeutics and the tag pipeline.
Shares Afuresertib, Laekna Therapeutics and the tag pipeline.
Shares Afuresertib, Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Cervical cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/